Jay R. Luly - 25 Nov 2025 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role: President and CEO, Director
Signature: /s/ Matthew Kowalsky as attorney-in-fact
Issuer symbol: ENTA
Transactions as of: 25 Nov 2025
Transactions value $: $0
Form type: 4
Filing time: 26 Nov 2025, 17:01:14 UTC
Previous filing: 12 Feb 2025
Next filing: 03 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Luly Jay R.	President and CEO, Director	C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN	/s/ Matthew Kowalsky as attorney-in-fact	26 Nov 2025	0001571211

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENTA	Stock Option (right to buy)	Award	$0	+310K		$0.00	310K	25 Nov 2025	Common Stock	310K	$13.66	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).